Biology subjects

Bouchard, L.

Publications and source records attributed to Bouchard, L..

6 recordsLinked to original sources

bioRxiv2026

Development of a microRNA clock for gestational age in the general population

IntroductionDNA methylation (DNAm) has shown promise as a biological marker of gestational age (GA). Here, we aimed to characterize how plasma circulating miRNAs - another epigenetic mechanism regulating gene expression - associate with GA at birth, and to construct a miRNA-based GA clock (miRClock-GA). MethodsWe leveraged 2083 umbilical cord plasma-derived circulating miRNAs from Generation R (N=1695). First, we performed linear regressions to identify miRNome-wide significant miRNAs associated with GA. Second, we applied elastic net regression to construct miRClock-GA. These steps were validated in Gen3G (N=213). Finally, we computed age acceleration (miRClock-AA) and evaluated association of miRClock-GA and miRClock-AA with child developmental outcomes up to 17 years of age, including comparisons with DNAmClocks. FindingsWe identified 123 miRNAs associated with GA, with miR-150-5p showing the strongest positive association ( B=0.244, SE=0.036, P=2.3e-11) and miR-373-3p the strongest negative association ( B=-0.255, SE=0.065, P=8.6e-5). MiRClock-GA correlated consistently with GA in Generation R train (rrange=0.62-0.72) and test sets (rrange=0.45-0.52) and in the independent validation cohort (rGen3G =0.33). Correlations between miRClock-GA and DNAmClocks were weak to moderate (rrange=0.28-0.42). MiRClock-AA explained significant variance in birthweight and childhood BMI beyond clinical GA. ConclusionsThis study reveals widespread associations between circulating miRNAs and GA, supports miRClock-GA as a consistent, well-performing biological marker of GA, with miRClock-AA predicting birthweight and childhood BMI beyond GA itself. Our findings provide a broader perspective on the potential utility of miRNAs as early markers of development. FundingE.U. Horizon Europe Research and Innovation Programme (FAMILY,No.101057529); European Research Council (TEMPO,No.101039672). Full funding in Acknowledgements. Research in contextO_ST_ABSEvidence before this studyC_ST_ABSEpigenetic clocks have emerged as powerful tools for assessing individual differences in biological ageing. Existing epigenetic clocks are typically constructed using DNA methylation (DNAm) data and are developed to estimate whether an individuals epigenetic age deviates relative to their chronological age. In adults, higher predicted biological epigenetic age than chronological age (accelerated epigenetic ageing) is an established indicator of mortality risk and other age-related morbidities. MicroRNAs are another epigenetic mechanism associated with chronological age and age-related phenotypes across species such as C. elegans, mice, primates and humans. Recently, a plasma-derived, cell-free circulating miRNA clock was developed in a sample of older European adults, with accelerated miRNA age predicting biological age-related conditions such as frailty and multi-system blood biomarkers. However, miRNA-based estimations of biological gestational age at birth have not been previously done and their relationship to child health outcomes are unknown. Added value of this studyTo gain a broader perspective on the role of epigenetic markers in biological gestational age at birth and the potential utility of miRNAs as early markers of (altered) development, we leveraged cord blood plasma circulating miRNA data collected at birth in a large population-based cohort. First, we identified 123 miRNAs associated with gestational age. Second, we used this information to construct a miRNA-based epigenetic clock for gestational age (miRClock-GA) and validated this clock in an independent cohort. MiRClock-GA showed moderate correlations with both gestational age and existing DNAm-based gestational clocks. Third, we found that miRClock-GA correlated cross-sectionally with birthweight, as well as prospectively with several adaptive, behavioural, cognitive, and growth outcomes measured up to age 17y, after taking into account maternal influences such as maternal education level, smoking, pre-pregnancy BMI, and age. Accelerated ageing of miRClock-GA (miRClock-AA) explained variance in birthweight and childhood BMI beyond clinical GA, after accounting for maternal influences. Implications of all available evidenceOur study provides the first large-scale evidence that circulating miRNAs in cord blood plasma show widespread associations with gestational age at birth and can be used to derive a robust biological marker of GA (MiRClock-GA), which explains a substantial proportion of the variation in clinical GA. MiRClock-AA provides information beyond GA in some child outcomes, such as BMI. These findings extend adult research, supporting the potential of miRNAs as promising markers for early risk assessment and health monitoring in a developmental context.

genomics↗

bioRxiv2024

BayesAge 2.0: A Maximum Likelihood Algorithm To Predict Transcriptomic Age

Aging is a complex biological process influenced by various factors, including genetic and environmental influences. In this study, we present BayesAge 2.0, an improved version of our maximum likelihood algorithm designed for predicting transcriptomic age (tAge) from RNA-seq data. Building on the original BayesAge framework, which was developed for epigenetic age prediction, BayesAge 2.0 integrates a Poisson distribution to model count-based gene expression data and employs LOWESS smoothing to capture non-linear gene-age relationships. BayesAge 2.0 provides significant improvements over traditional linear models, such as Elastic Net regression. Specifically, it addresses issues of age bias in predictions, with minimal age-associated bias observed in residuals. Its computational efficiency further distinguishes it from traditional models, as reference construction and cross-validation are completed more quickly compared to Elastic Net regression, which requires extensive hyperparameter tuning. Overall, BayesAge 2.0 represents a notable advance in transcriptomic age prediction, offering a robust, accurate, and efficient tool for aging research and biomarker development.

bioinformatics↗

bioRxiv2019

Placental DNA methylation signatures of maternal smoking during pregnancy and potential impacts on fetal growth

Maternal smoking during pregnancy (MSDP) contributes to poor birth outcomes, in part through disrupted placental functions, which may be reflected in the placental epigenome. We meta-analyzed the associations between MSDP and placental DNA methylation (DNAm) and between DNAm and birth outcomes within the Pregnancy And Childhood Epigenetics (PACE) consortium (7 studies, N=1700, 344 with any MSDP). We identified 1224 CpGs that were associated with MSDP, of which 341 associated with birth outcomes and 141 associated with gene expression. Only 6 of these CpGs were consistent with the findings from a prior meta-analysis of cord blood DNAm, demonstrating substantial tissue-specific responses to MSDP. The placental MSDP associated CpGs were enriched for growth-factor signaling, hormone activity, inflammation, and vascularization, which play important roles in placental function. We demonstrate links between placental DNAm, MSDP and poor birth outcomes, which may better inform the mechanisms through which MSDP impacts placental function and fetal growth.

genomics↗

bioRxiv2017

Placenta DNA Methylation Adaptation to Maternal Glucose Tolerance in Pregnancy

Maternal hyperglycemia during pregnancy is associated with fetal growth and adverse perinatal and developmental outcomes. Placental epigenetic maladaptation may underlie these associations. We performed an epigenome-wide association study of term placentas and prenatal maternal glucose response 2-hour post oral glucose challenge at 24-30 weeks of gestation among 448 mother-infant pairs. Maternal glucose levels post-load were strongly associated with lower DNA methylation of 4 CpGs (FDR q<0.05) within the Phosphodiesterase 4B gene (PDE4B). Additionally, three other CpGs were differentially methylated relative to maternal glucose response within the TNFRSF1B; LDLR; and BLM genes (FDR q<0.05). Methylation levels correlated with expression in placental tissue for all 4 CpG sites in PDE4B (rs: 0.26-0.35, P<0.01), LDLR (rs: 0.22, P=0.03) and at TNFRSF1B (rs: -0.25, P=0.01). Our study provides evidence that maternal glucose response during pregnancy is associated with DNA methylation of genes within the placenta that are partially under epigenetic control.

genomics↗

bioRxiv2017

Maternal and fetal genetic contribution to gestational weight gain

BackgroundClinical recommendations to limit gestational weight gain (GWG) imply high GWG is causally related to adverse outcomes in mother or offspring, but GWG is the sum of several inter-related complex phenotypes (maternal fat deposition and vascular expansion, placenta, amniotic fluid and fetal growth). Understanding the genetic contribution to GWG could help clarify the potential effect of its different components on maternal and offspring health. Here we explore the genetic contribution to total, early and late GWG.\n\nParticipants and MethodsA genome-wide association study was used to identify maternal and fetal variants contributing to GWG in up to 10,543 mothers and up to 16,317 offspring of European origin, with replication in 10,660 mothers and 7,561 offspring. Additional analyses determined the proportion of variability in GWG from maternal and fetal common genetic variants and the overlap of established genome-wide significant variants for phenotypes relevant to GWG (e.g. maternal BMI and glucose, birthweight).\n\nResultsWe found that approximately 20% of the variability in GWG was tagged by common maternal genetic variants, and that the fetal genome made a surprisingly minor contribution to explaining variation in GWG. We were unable to identify any genetic variants that reached genome-wide levels of significance (P<5x10-8) and replicated. Some established maternal variants associated with increased BMI, fasting glucose and type 2 diabetes were associated with lower early, and higher later GWG. Maternal variants related to higher systolic blood pressure were related to lower late GWG. Established maternal and fetal birthweight variants were largely unrelated to GWG.\n\nConclusionWe found a modest contribution of maternal common variants to GWG and some overlap of maternal BMI, glucose and type 2 diabetes variants with GWG. These findings suggest that associations between GWG and later offspring/maternal outcomes may be due to the relationship of maternal BMI and diabetes with GWG.

genetics↗

bioRxiv2017

An analytic approach for interpretable predictive models in high dimensional data, in the presence of interactions with exposures

Predicting a phenotype and understanding which variables improve that prediction are two very challenging and overlapping problems in analysis of high-dimensional data such as those arising from genomic and brain imaging studies. It is often believed that the number of truly important predictors is small relative to the total number of variables, making computational approaches to variable selection and dimension reduction extremely important. To reduce dimensionality, commonly-used two-step methods first cluster the data in some way, and build models using cluster summaries to predict the phenotype.\n\nIt is known that important exposure variables can alter correlation patterns between clusters of high-dimensional variables, i.e., alter network properties of the variables. However, it is not well understood whether such altered clustering is informative in prediction. Here, assuming there is a binary exposure with such network-altering effects, we explore whether use of exposure-dependent clustering relationships in dimension reduction can improve predictive modelling in a two-step framework. Hence, we propose a modelling framework called ECLUST to test this hypothesis, and evaluate its performance through extensive simulations.\n\nWith ECLUST, we found improved prediction and variable selection performance compared to methods that do not consider the environment in the clustering step, or to methods that use the original data as features. We further illustrate this modelling framework through the analysis of three data sets from very different fields, each with high dimensional data, a binary exposure, and a phenotype of interest. Our method is available in the eclust CRAN package.

genomics↗